Ofatumumab

ABC1183 is an orally active selective dual GSK3 and CDK9 inhibitor. ABC1183 inhibits GSK3β, GSK3α and CDK9/cyclin T1 with the IC 50 values of 657 nM, 327 nM and 321 nM, respectively. ABC1183 has anti-inflammatory and anti-tumor activitiesIn

ABC1183 is an orally active selective dual GSK3 and CDK9 inhibitor. ABC1183 inhibits GSK3β, GSK3α and CDK9/cyclin T1 with the IC 50 values of 657 nM, 327 nM and 321 nM, respectively. ABC1183 has anti-inflammatory and anti-tumor activitiesIn

ABC1183 is an orally active selective dual GSK3 and CDK9 inhibitor. ABC1183 inhibits GSK3β, GSK3α and CDK9/cyclin T1 with the IC 50 values of 657 nM, 327 nM and 321 nM, respectively. ABC1183 has anti-inflammatory and anti-tumor activitiesIn

ABC1183 is an orally active selective dual GSK3 and CDK9 inhibitor. ABC1183 inhibits GSK3β, GSK3α and CDK9/cyclin T1 with the IC 50 values of 657 nM, 327 nM and 321 nM, respectively. ABC1183 has anti-inflammatory and anti-tumor activitiesIn

Mouse anti Human ABCF2 Antibody, Monoclonal (OTI8F4), could be used for WB, IHC and so on.

Mouse anti Human ABCF2 Antibody, Monoclonal (OTI8F4), could be used for WB, IHC and so on.

Mouse anti Human ABCF2 Antibody, Monoclonal (OTI8F4), could be used for WB, IHC and so on.

Mouse anti Human ABCF2 Antibody, Monoclonal (OTI8F4), could be used for WB, IHC and so on.

ABR-238901 is an orally active and potent S100A8/A9 blocker and inhibits S100A8/A9 interaction with its receptors RAGE (receptor for advanced glycation endproducts) and TLR4 (toll-like receptor 4). ABR-238901 has the potential for myocardial

BH3 mimetic and Bcl-2 inhibitor. It induces apoptosis in chronic lymphocytic leukemia cells

A BH3 mimetic that selectively inhibits Bcl-2 (Ki 3-fold less avidly to the related family proteins, Bcl-xL and Bcl-W (Kis = 48 and 245 nM, respectively) inhibits the growth of Bcl-2-dependent cell lines and in vivo tumor xenografts and

A BH3 mimetic that selectively inhibits Bcl-2 (Ki 3-fold less avidly to the related family proteins, Bcl-xL and Bcl-W (Kis = 48 and 245 nM, respectively) inhibits the growth of Bcl-2-dependent cell lines and in vivo tumor xenografts and